DOI QR코드

DOI QR Code

Combined Effect of Granulocyte-Colony-Stimulating Factor-Induced Bone Marrow-Derived Stem Cells and Red Ginseng in Patients with Decompensated Liver Cirrhosis (Combined Effect of G-CSF and Red Ginseng in Liver Cirrhosis)

  • Kim, Hyun Hee (Department of Internal Medicine, Catholic University of Daegu School of Medicine) ;
  • Kim, Seung Mo (Department of Internal Medicine, College of Korean Medicine, Daegu Haany University) ;
  • Kim, Kyung Soon (Department of Internal Medicine, College of Korean Medicine, Daegu Haany University) ;
  • Kwak, Min A (Department of Internal Medicine, College of Korean Medicine, Daegu Haany University) ;
  • Kim, Sang Gyung (Department of Laboratory Medicine, Catholic University of Daegu School of Medicine) ;
  • Kim, Byung Seok (Department of Internal Medicine, Catholic University of Daegu School of Medicine) ;
  • Lee, Chang Hyeong (Department of Internal Medicine, Catholic University of Daegu School of Medicine)
  • Received : 2016.08.31
  • Accepted : 2016.12.30
  • Published : 2016.12.31

Abstract

Objectives: Granulocyte-colony-stimulating factor (G-CSF) mobilized bone marrow (BM)-derived hematopoietic stem cells could contribute to improvement of liver function. In addition, liver fibrosis can reportedly be prevented by the Rg 1 component of red ginseng. This study investigated the combined effect of G-CSF and red ginseng on decompensated liver cirrhosis. Methods: Four patients with decompensated liver cirrhosis were injected with G-CSF to proliferate BM stem cells for 4 days ($5{\mu}g/kg$ bid subcutaneously) and followed-up for 3 months. The patients also received red ginseng for 4 days (2 tablets tid per os). We analyzed Child-Pugh scores, Model for End-Stage Liver Disease (MELD) scores and cirrhotic complications. Results: All patients showed marked increases in White blood cell (WBC) and CD34+ cells in the peripheral blood, with a peak time of 4 days after G-CSF injection. Spleen size also increased after G-CSF injection, but not severely. At end of the study, 2 patients showed improvement in Child-Pugh scores, hepatic encephalopathy, and refractory ascites. During the clinical trial period, none of the 4 patients showed any other adverse events or deterioration of liver function. Conclusions: We conclude that G-CSF/red ginseng combination therapy is relatively effective in improving liver function and major complications of decompensated liver cirrhosis without adverse effects. Further clinical trials are warranted to assess the clinical effects of G-CSF for decompensated liver cirrhosis.

Acknowledgement

Supported by : Integrative Medicine Institute

References

  1. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol. 2001;34:84-91. https://doi.org/10.1016/S0168-8278(01)81171-5
  2. Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, et al. De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transplant Proc. 2012;44:802-805. https://doi.org/10.1016/j.transproceed.2012.01.027
  3. Preston SL, Alison MR, Forbes SJ, Direkze NC, Poulsom R, Wright NA. The new stem cell biology: something for everyone. Mol Pathol. 2003;56:86-96. https://doi.org/10.1136/mp.56.2.86
  4. am Esch JS 2nd, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells. 2005;23:463-470. https://doi.org/10.1634/stemcells.2004-0283
  5. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006;24:2292-2298. https://doi.org/10.1634/stemcells.2005-0542
  6. Yannaki E, Anagnostopoulos A, Kapetanos D, Xagorari A, Iordanidis F, Batsis I, et al. Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp Hematol. 2006;34:1583-1587. https://doi.org/10.1016/j.exphem.2006.06.012
  7. Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al-Allaf F, et al. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 2006;24:1822-1830. https://doi.org/10.1634/stemcells.2005-0629
  8. Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011;54:820-828. https://doi.org/10.1002/hep.24434
  9. Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009;21:1199-1205. https://doi.org/10.1097/MEG.0b013e32832a1f6c
  10. Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levicar N, et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol. 2008;103:1952-1958. https://doi.org/10.1111/j.1572-0241.2008.01993.x
  11. Han Y, Yan L, Han G, Zhou X, Hong L, Yin Z, et al. Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte-colony-11stimulating factor mobilization therapy. Cytotherapy. 2008;10:390-396. https://doi.org/10.1080/14653240802129901
  12. Yan L, Han Y, Wang J, Liu J, Hong L, Fan D. Peripheral blood monocytes from patients with HBV related decompensated liver cirrhosis can differentiate into functional hepatocytes. Am J Hematol. 2007;82:949-954. https://doi.org/10.1002/ajh.21030
  13. Geng J, Peng W, Huang Y, Fan H, Li S. Ginsenoside-Rg1 from Panax notoginseng prevents hepatic fibrosis induced by thioacetamide in rats. Eur J Pharmacol. 2010;634:162-169. https://doi.org/10.1016/j.ejphar.2010.02.022
  14. Peng XD, Dai LL, Huang CQ, He CM, Yang B, Chen LJ. Relationship between anti-fibrotic effect of Panax notoginseng saponins and serum cytokines in rat hepatic fibrosis. Biochem Biophys Res Commun. 2009;388:31-34. https://doi.org/10.1016/j.bbrc.2009.07.099
  15. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology. 1984; 4:430-435. https://doi.org/10.1002/hep.1840040313
  16. Terai S, Sakaida I, Yamamoto N, Omori K, Watanabe T, Ohata S, et al. An in vivo model for monitoring trans-differentiation of bone marrow cells into functional hepatocytes. J Biochem (Tokyo). 2003;134:551-558. https://doi.org/10.1093/jb/mvg173
  17. Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology. 2004;40:1304-1311. https://doi.org/10.1002/hep.20452
  18. Terai S, Sakaida I, Nishina H, Okita K. Lesson from the GFP/CCl4 model-translational research project: The development of cell therapy using autologous bone marrow cells in patients with liver cirrhosis. J Hepatobiliary Pancreat Surg. 2005;12:203-207. https://doi.org/10.1007/s00534-005-0977-0
  19. Gaia S, Smedile A, Omede P, Olivero A, Sanavio F, Balzola F, et al. Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol. 2006;45:13-19. https://doi.org/10.1016/j.jhep.2006.02.018
  20. Handgretinger R, Gordon PR, Leimig T, Chen X, Buhring HJ, Niethammer D, et al. Biology and plasticity of CD133+ hematopoietic stem cells. Ann N Y Acad Sci. 2003;996:141-151. https://doi.org/10.1111/j.1749-6632.2003.tb03242.x
  21. Potgens AJ, Schmitz U, Kaufmann P, Frank HG. Monoclonal antibody CD133-2 (AC141) against hematopoietic stem cell antigen CD133 shows crossreactivity with cytokeratin 18. JHistochem Cytochem. 2002;50:1131-1134. https://doi.org/10.1177/002215540205000814
  22. Geng JW, Peng W, Huang YG, Fan H, Li SD. Gnisengoside-Rg1 from Panax notoginseng prevents heaptic fibrosis induced by thioacetamide in rats. Euro J Pharm. 2010;634:162-169 https://doi.org/10.1016/j.ejphar.2010.02.022
  23. Peng Xd, Dai Ll, Huang CQ, He CM, Yang B, Chen LJ. Relationship between anti-fibrotic effect of Panax notoginseng saponins and serum cytokines in rat hepatic fibrosis Biochemical and Biophysical Research Communications. 2009;388:31-34. https://doi.org/10.1016/j.bbrc.2009.07.099
  24. Lee NH, Son CG. Systematic Review of Randomized Controlled Trials Evaluating the Efficacy and Safety of Ginseng. J Acupunct Meridian Stud. 2011;4:85-97 https://doi.org/10.1016/S2005-2901(11)60013-7
  25. Shimizu H, Miyazaki M, Wakabayashi Y, Mitsuhashi N, Kato A, Ito H, et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol. 2001;34:683-689. https://doi.org/10.1016/S0168-8278(00)00055-6
  26. Becker PS, Wagle M, Matous S, Swanson RS, Pihan G, Lowry PA, et al. Spontaneous splenic rupture following administration of granulocyte -colony-stimulating factor (GCSF): occurrence in an allogeneic donor of periperal blood stem cells. Biol Blood Marrow Transplant. 1997;3(6):341-343.
  27. Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J. Splenic rupture after granulocyte -colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion. 2004;44:1260-1261. https://doi.org/10.1111/j.1537-2995.2004.00413.x